Redirecting T cells to glypican-3 with 28.41BB.ζ and 28.ζ-41BBL CARs for hepatocellular carcinoma treatment

Protein Cell. 2018 Jul;9(7):664-669. doi: 10.1007/s13238-017-0489-0.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology*
  • Carcinoma, Hepatocellular / drug therapy*
  • Carcinoma, Hepatocellular / immunology
  • Carcinoma, Hepatocellular / pathology
  • Cytokines / immunology
  • Drug Screening Assays, Antitumor
  • Glypicans / antagonists & inhibitors*
  • Glypicans / immunology
  • Humans
  • Ligands
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / immunology
  • Liver Neoplasms / pathology
  • T-Lymphocytes / drug effects*
  • T-Lymphocytes / immunology

Substances

  • Antineoplastic Agents
  • Cytokines
  • GPC3 protein, human
  • Glypicans
  • Ligands